Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sofetabart mipitecan
- Development stage
- Phase 3
- Lead developer
- Eli Lilly
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Sofetabart mipitecan (LY4170156)** is a novel **antibody-drug conjugate (ADC)** developed by **Eli Lilly and Company** that targets **folate receptor alpha (FRα)**, a protein overexpressed on ovarian cancer cells. It consists of a monoclonal antibody linked to an **exatecan payload**, a topoisomerase I inhibitor, enabling targeted delivery of the cytotoxic agent to FRα-expressing tumors, potentially improving efficacy and reducing off-target toxicity compared to systemic chemotherapy. It is currently being evaluated in the phase 3 **GOG-3133/FRAmework-01** trial for **platinum-resistant** and **platinum-sensitive recurrent ovarian cancer**, including peritoneal and fallopian tube cancers, with part A comparing it to chemotherapy or mirvetuximab soravtansine, and part B assessing it plus bevacizumab versus platinum-based chemotherapy plus bevacizumab.[1][11]
- Other names
- sofetabart mipitecan
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on sofetabart mipitecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sofetabart mipitecan.